Vice: Killing Cancer

[NFLTrends]

EXEL - 3.56 Up 0.04(1.14%) Jun 12, 4:00PM EDT

 

[NFLTrends]

Exelixis, Inc. (EXEL) -NasdaqGS  Watchlist


5.90 Up 0.01(0.17%) Aug 7, 4:00PM EDT

UP $2.79 per share as of today!

After Hours : 5.90 0.00 (0.00%) Aug 7, 7:59PM EDT

 

[NFLTrends]

Exelixis Inc. (NASDAQ: EXEL) is scheduled for a PDUFA review on November 11 for its cobimetinib. Specifically, cobimetinib is used in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma harboring a BRAF V600 mutation